These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 21733056)

  • 1. Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients.
    Dobbins RL; O'Connor-Semmes R; Kapur A; Kapitza C; Golor G; Mikoshiba I; Tao W; Hussey EK
    Diabetes Obes Metab; 2012 Jan; 14(1):15-22. PubMed ID: 21733056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus.
    Kapur A; O'Connor-Semmes R; Hussey EK; Dobbins RL; Tao W; Hompesch M; Smith GA; Polli JW; James CD; Mikoshiba I; Nunez DJ
    BMC Pharmacol Toxicol; 2013 May; 14():26. PubMed ID: 23668634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial.
    Dharmalingam M; Aravind SR; Thacker H; Paramesh S; Mohan B; Chawla M; Asirvatham A; Goyal R; Shembalkar J; Balamurugan R; Kadam P; Alva H; Kodgule R; Tandon M; Vaidyanathan S; Pendse A; Gaikwad R; Katare S; Suryawanshi S; Barkate H
    Drugs; 2020 Apr; 80(6):587-600. PubMed ID: 32162274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of safety and tolerability of remogliflozin etabonate (GSK189075) when administered with total daily dose of 2000 mg of metformin.
    Dobbins R; Hussey EK; O'Connor-Semmes R; Andrews S; Tao W; Wilkison WO; Cheatham B; Sagar K; Hanmant B
    BMC Pharmacol Toxicol; 2021 Jun; 22(1):34. PubMed ID: 34120651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus.
    Hussey EK; Kapur A; O'Connor-Semmes R; Tao W; Rafferty B; Polli JW; James CD; Dobbins RL
    BMC Pharmacol Toxicol; 2013 Apr; 14():25. PubMed ID: 23631443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Remogliflozin etabonate: a novel SGLT2 inhibitor for treatment of diabetes mellitus.
    Mikhail N
    Expert Opin Investig Drugs; 2015; 24(10):1381-7. PubMed ID: 26288025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2, improves serum glucose profiles in type 1 diabetes.
    Mudaliar S; Armstrong DA; Mavian AA; O'Connor-Semmes R; Mydlow PK; Ye J; Hussey EK; Nunez DJ; Henry RR; Dobbins RL
    Diabetes Care; 2012 Nov; 35(11):2198-200. PubMed ID: 23011728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus.
    Schwartz SL; Akinlade B; Klasen S; Kowalski D; Zhang W; Wilpshaar W
    Diabetes Technol Ther; 2011 Dec; 13(12):1219-27. PubMed ID: 21854192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized efficacy and safety trial of once-daily remogliflozin etabonate for the treatment of type 2 diabetes.
    Sykes AP; Kemp GL; Dobbins R; O'Connor-Semmes R; Almond SR; Wilkison WO; Walker S; Kler L
    Diabetes Obes Metab; 2015 Jan; 17(1):98-101. PubMed ID: 25238025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus.
    Veltkamp SA; van Dijk J; Collins C; van Bruijnsvoort M; Kadokura T; Smulders RA
    Clin Ther; 2012 Aug; 34(8):1761-71. PubMed ID: 22795925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study.
    Ji L; Ma J; Li H; Mansfield TA; T'joen CL; Iqbal N; Ptaszynska A; List JF
    Clin Ther; 2014 Jan; 36(1):84-100.e9. PubMed ID: 24378206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.
    Devineni D; Morrow L; Hompesch M; Skee D; Vandebosch A; Murphy J; Ways K; Schwartz S
    Diabetes Obes Metab; 2012 Jun; 14(6):539-45. PubMed ID: 22226086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models.
    Fujimori Y; Katsuno K; Nakashima I; Ishikawa-Takemura Y; Fujikura H; Isaji M
    J Pharmacol Exp Ther; 2008 Oct; 327(1):268-76. PubMed ID: 18583547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.
    Bolinder J; Ljunggren Ö; Johansson L; Wilding J; Langkilde AM; Sjöström CD; Sugg J; Parikh S
    Diabetes Obes Metab; 2014 Feb; 16(2):159-69. PubMed ID: 23906445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized trial showing efficacy and safety of twice-daily remogliflozin etabonate for the treatment of type 2 diabetes.
    Sykes AP; O'Connor-Semmes R; Dobbins R; Dorey DJ; Lorimer JD; Walker S; Wilkison WO; Kler L
    Diabetes Obes Metab; 2015 Jan; 17(1):94-7. PubMed ID: 25223369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride].
    Strojek K; Yoon KH; Hruba V; Elze M; Langkilde AM; Parikh S
    Dtsch Med Wochenschr; 2013 Apr; 138 Suppl 1():S16-26. PubMed ID: 23529567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin.
    Kadokura T; Zhang W; Krauwinkel W; Leeflang S; Keirns J; Taniuchi Y; Nakajo I; Smulders R
    Clin Pharmacokinet; 2014 Nov; 53(11):975-88. PubMed ID: 25316572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus.
    Sha S; Polidori D; Heise T; Natarajan J; Farrell K; Wang SS; Sica D; Rothenberg P; Plum-Mörschel L
    Diabetes Obes Metab; 2014 Nov; 16(11):1087-95. PubMed ID: 24939043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease.
    Yale JF; Bakris G; Cariou B; Yue D; David-Neto E; Xi L; Figueroa K; Wajs E; Usiskin K; Meininger G
    Diabetes Obes Metab; 2013 May; 15(5):463-73. PubMed ID: 23464594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Remogliflozin Etabonate: First Global Approval.
    Markham A
    Drugs; 2019 Jul; 79(10):1157-1161. PubMed ID: 31201711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.